JP2012506439A - イメージング及び放射線治療法 - Google Patents

イメージング及び放射線治療法 Download PDF

Info

Publication number
JP2012506439A
JP2012506439A JP2011533266A JP2011533266A JP2012506439A JP 2012506439 A JP2012506439 A JP 2012506439A JP 2011533266 A JP2011533266 A JP 2011533266A JP 2011533266 A JP2011533266 A JP 2011533266A JP 2012506439 A JP2012506439 A JP 2012506439A
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
fluoro
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011533266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506439A5 (enExample
Inventor
カスバートソン，アラン
イヴソン，ピーター・ブライアン
バッラ，ラジヴ
クニイール・クランガラ，ヴィジャヤ・ラジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
General Electric Co
Original Assignee
GE Healthcare Ltd
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd, General Electric Co filed Critical GE Healthcare Ltd
Publication of JP2012506439A publication Critical patent/JP2012506439A/ja
Publication of JP2012506439A5 publication Critical patent/JP2012506439A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011533266A 2008-10-21 2009-10-20 イメージング及び放射線治療法 Pending JP2012506439A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10700108P 2008-10-21 2008-10-21
US61/107,001 2008-10-21
GB0819280.9 2008-10-21
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods
PCT/US2009/061271 WO2010048144A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods

Publications (2)

Publication Number Publication Date
JP2012506439A true JP2012506439A (ja) 2012-03-15
JP2012506439A5 JP2012506439A5 (enExample) 2013-05-09

Family

ID=40097766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533266A Pending JP2012506439A (ja) 2008-10-21 2009-10-20 イメージング及び放射線治療法

Country Status (12)

Country Link
US (1) US20110286922A1 (enExample)
EP (1) EP2349351A2 (enExample)
JP (1) JP2012506439A (enExample)
KR (1) KR20110074988A (enExample)
CN (1) CN102186505A (enExample)
AU (1) AU2009307783A1 (enExample)
BR (1) BRPI0919690A2 (enExample)
CA (1) CA2738955A1 (enExample)
GB (1) GB0819280D0 (enExample)
MX (1) MX2011004161A (enExample)
RU (1) RU2011113996A (enExample)
WO (1) WO2010048144A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514702A (ja) * 2012-03-30 2015-05-21 ゼネラル・エレクトリック・カンパニイ Ｈｐｌｃフリー放射性ヨウ素化のためのビオチンスタナン
WO2017187717A1 (ja) * 2016-04-28 2017-11-02 国立大学法人名古屋大学 蛍光プローブ、蛍光検出方法及び蛍光プローブの使用方法
JP2019525762A (ja) * 2016-07-28 2019-09-12 アドバンスト バイオデザイン Ａｌｄｈアイソザイムの特異的基質
WO2021153772A1 (ja) * 2020-01-31 2021-08-05 国立大学法人 東京大学 アルデヒドデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US8535641B2 (en) 2004-03-02 2013-09-17 Cellectar, Inc. Phospholipid analogs as diapeutic* agents and methods thereof
CU23844B1 (es) * 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
SI3708192T1 (sl) * 2009-06-12 2023-12-29 Cellectar, Inc. Eter fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
US20120251449A1 (en) * 2009-12-22 2012-10-04 Vijaya Raj Kuniyil Kulangara Aldh: a compound for cancer stem cell imaging
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013012754A1 (en) * 2011-07-15 2013-01-24 University Of Southern California Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same
WO2013048832A1 (en) * 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US20160008493A1 (en) * 2013-03-15 2016-01-14 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
KR101941223B1 (ko) * 2017-04-04 2019-01-22 을지대학교 산학협력단 복강경 수술용 삼중 융합영상장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528672A (ja) * 2005-02-04 2008-07-31 ジーイー・ヘルスケア・リミテッド カスパーゼ−３基質含有造影剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
AU2003228744A1 (en) * 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
EP1996182A4 (en) * 2006-02-27 2009-08-12 Univ Johns Hopkins CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
US20080187938A1 (en) * 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528672A (ja) * 2005-02-04 2008-07-31 ジーイー・ヘルスケア・リミテッド カスパーゼ−３基質含有造影剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6013055681; Ｃｅｌｌ　Ｓｔｅｍ　Ｃｅｌｌ Ｖｏｌ．１，　Ｎｏ．５, 2007, ｐ．４８５-４８７ *
JPN6013055685; Ｃｅｌｌ　Ｓｔｅｍ　Ｃｅｌｌ Ｖｏｌ．１，　Ｎｏ．５, 2007, ｐ．５５５-５６７ *
JPN6013055688; Ｊｏｕｒｎａｌ　ｏｆ　Ｌａｂｅｌｌｅｄ　Ｃｏｍｐｏｕｎｄｓ　＆　Ｒａｄｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｖｏｌ．４９，　Ｎｏ．３, 2006, ｐ．２５３-２６２ *
JPN6013055690; Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ Ｖｏｌ．９１４，　Ｎｏ．２, 1987, ｐ．１６２-１６９ *
JPN6013055693; Ｅｘｐｅｒｉｍｅｎｔａｌ　ａｎｄ　Ｔｏｘｉｃｏｌｏｇｉｃ　Ｐａｔｈｏｌｏｇｙ Ｖｏｌ．５３，　Ｎｏ．１, 2001, ｐ．７７-８０ *
JPN6013055695; Ａｎａｌｙｔｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２４５，　Ｎｏ．１, 1997, ｐ．６９-７８ *
JPN6013055697; Ｂｌｏｏｄ Ｖｏｌ．８５，　Ｎｏ．１０, 1995, ｐ．２７４２-２７４６ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514702A (ja) * 2012-03-30 2015-05-21 ゼネラル・エレクトリック・カンパニイ Ｈｐｌｃフリー放射性ヨウ素化のためのビオチンスタナン
WO2017187717A1 (ja) * 2016-04-28 2017-11-02 国立大学法人名古屋大学 蛍光プローブ、蛍光検出方法及び蛍光プローブの使用方法
JPWO2017187717A1 (ja) * 2016-04-28 2019-02-28 国立大学法人名古屋大学 蛍光プローブ、蛍光検出方法及び蛍光プローブの使用方法
JP2019525762A (ja) * 2016-07-28 2019-09-12 アドバンスト バイオデザイン Ａｌｄｈアイソザイムの特異的基質
JP7050748B2 (ja) 2016-07-28 2022-04-08 アドヴァンスト・バイオデザイン Ａｌｄｈアイソザイムの特異的基質
US11519014B2 (en) 2016-07-28 2022-12-06 Advanced Biodesign Specific substrate of an ALDH isoenzyme
WO2021153772A1 (ja) * 2020-01-31 2021-08-05 国立大学法人 東京大学 アルデヒドデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Also Published As

Publication number Publication date
US20110286922A1 (en) 2011-11-24
CA2738955A1 (en) 2010-04-29
MX2011004161A (es) 2011-06-06
EP2349351A2 (en) 2011-08-03
KR20110074988A (ko) 2011-07-05
RU2011113996A (ru) 2012-11-27
AU2009307783A1 (en) 2010-04-29
WO2010048144A3 (en) 2010-07-22
BRPI0919690A2 (pt) 2015-12-08
CN102186505A (zh) 2011-09-14
GB0819280D0 (en) 2008-11-26
WO2010048144A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
JP2012506439A (ja) イメージング及び放射線治療法
US20120244074A1 (en) Labelled integrin binders
US20110236307A1 (en) In vivo imaging method
EP2305316A2 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
JP5709841B2 (ja) 標識分子イメージング剤、製造方法及び使用方法
US11844846B2 (en) Styrylbenzothiazole derivatives and uses in imaging methods
JP2009538894A (ja) インビボイメージング化合物としての四環式オキサゼピン類
JP2009518373A (ja) 線維症用の新規造影剤
US20120003154A1 (en) Aryloxyanilide derivatives
US20120034165A1 (en) Imaging the central nervous system with purinergic p2x7 receptor binding agents
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
WO2013048832A1 (en) 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) Imaging and radiotherapy methods for tumour stem cells
US20100247435A1 (en) Measurement of neural activity
US20130101509A1 (en) Imaging and radiotherapy methods
CN101970017B (zh) 中枢神经系统的显像
US12138320B2 (en) Composition and methods for tumor imaging and treatment
US20080279771A1 (en) Novel Imaging Agents for Cancer
WO2013131872A1 (en) Imaging neural activity
EP2309926A1 (en) Treatment monitoring

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140422